These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9228240)

  • 41. From the National Institutes of Health.
    Wyngaarden JB
    JAMA; 1986 Sep; 256(9):1097. PubMed ID: 3525879
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gonadotrophin-releasing hormone agonists induce osteoporosis.
    Maillefert JF; Sibilia J; Kuntz JL; Tavernier C
    Br J Rheumatol; 1994 Dec; 33(12):1199-200. PubMed ID: 8000764
    [No Abstract]   [Full Text] [Related]  

  • 44. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
    Gillis D; Karavani G; Hirsch HJ; Strich D
    J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
    Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
    Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist.
    Klein KO; Baron J; Barnes KM; Pescovitz OH; Cutler GB
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2387-9. PubMed ID: 9661615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height.
    Comite F; Cassorla F; Barnes KM; Hench KD; Dwyer A; Skerda MC; Loriaux DL; Cutler GB; Pescovitz OH
    JAMA; 1986 May; 255(19):2613-6. PubMed ID: 3084811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist.
    Harris DA; Van Vliet G; Egli CA; Grumbach MM; Kaplan SL; Styne DM; Vainsel M
    J Clin Endocrinol Metab; 1985 Jul; 61(1):152-9. PubMed ID: 3889035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome.
    Siomou E; Kosmeri C; Pavlou M; Vlahos AP; Argyropoulou MI; Siamopoulou A
    Pediatr Nephrol; 2014 Sep; 29(9):1633-6. PubMed ID: 24604705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term results of long-acting luteinizing-hormone-releasing hormone agonist in central precocious puberty.
    Swaenepoel C; Chaussain JL; Roger M
    Horm Res; 1991; 36(3-4):126-30. PubMed ID: 1840142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog.
    Pescovitz OH; Comite F; Cassorla F; Dwyer AJ; Poth MA; Sperling MA; Hench K; McNemar A; Skerda M; Loriaux DL
    J Clin Endocrinol Metab; 1984 May; 58(5):857-61. PubMed ID: 6368580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Undulating course of precocious puberty].
    Kolmer M; Schulz U; Herkner K; Frisch H; Waldhauser F
    Padiatr Padol; 1991; 26(6):271-4. PubMed ID: 1838804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion.
    Saggese G; Bertelloni S; Baroncelli GI; Pardi D; Cinquanta L
    J Endocrinol Invest; 1991 Mar; 14(3):231-6. PubMed ID: 1830057
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hormonal pharmacotherapy: balancing between politics and evidence-based medicine].
    van Panhuis PJ
    Tijdschr Psychiatr; 2007; 49(2):117-8. PubMed ID: 17290341
    [No Abstract]   [Full Text] [Related]  

  • 59. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
    Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Indications of GnRH agonist therapy during childhood].
    Carel JC
    Bull Acad Natl Med; 2012 Feb; 196(2):345-55. PubMed ID: 23420954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.